신경조절(Neuromodulation) 시장 : 2027년까지의 세계 예측

출판 : MarketsandMarkets(마켓츠앤마켓츠)출판년월 : 2022년08월

신경조절(Neuromodulation) 시장 : 유형 [내부(심부 뇌 자극, 미주 신경 자극), 외부(경두개 자기 자극)], 용도(파킨슨병, 우울증, 요실금, 간질, 비만) – 2027년까지의 세계 예측
Neuromodulation Market by Type (Internal (Deep Brain Stimulation, Vagus Nerve Stimulation), External (Transcranial Magnetic Stimulation)), Application (Parkinson’s Disease, Depression, Urine incontinence, Epilepsy, Obesity) – Global Forecast to 2027

페이지수 207
도표수 246
구성 영문조사보고서
가격 이곳을 눌러주세요

리포트목차    주문/문의    납기/라이센스안내

Sample Request

The global neuromodulation market is valued at an estimated USD 6.0 billion in 2022 and is projected to reach USD 10.4 billion by 2027, at a CAGR of 11.8% during the forecast period. Market growth is driven by factors such as the growing incidence of rising incidence of Parkinson’s disease, high incidence of urine incontinence, extensive use of external neuromodulation in healthcare, low cost and ease of use are the major factors hampering the growth of this market.
전 세계 신경조절 시장의 가치는 2022년에 60억 달러로 추산되며 예측 기간 동안 CAGR 11.8%로 2027년까지 104억 달러에 이를 것으로 예상됩니다. 시장 성장은 파킨슨 병 발병률 증가, 요실금 발병률 증가, 의료 분야에서 외부 신경 조절의 광범위한 사용, 저렴한 비용 및 사용 용이성과 같은 요인에 의해 주도되며 이 시장의 성장을 방해하는 주요 요인입니다.

세계 신경조절 시장

“The internal neuromodulation segment accounted for the highest growth rate in the neuromodulation market, by product, during the forecast period”
The neuromodulation market is segmented into Internal neuromodulation and external neuromodulation. The internal neuromodulation is expected to register the highest growth rate during the forecast period. Factors such as the minimally invasive nature, reduced physical impact and improved quality of life are contributing to the growth of this segment.
“Deep Brain Stimulation segment accounted for the highest CAGR”
Based on type, the internal neuromodulation market is segmented into spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS), sacral nerve stimulation (SNS), and gastric electrical stimulation (GES). Deep brain stimulation segment is expected to register highest growth rate during forecast period as DBS is a minimally invasive technique that allows the stimulation parameters to be changed to reduce side effects.

Neuromodulation Market
“The Asia Pacific market is expected to grow at the highest CAGR during the forecast period”
The global neuromodulation market is segmented into five regions – North America, Europe, the Asia Pacific, and Rest of the World. The Asia Pacific region is expected to witness the highest growth in the neuromodulation market during the forecast period. The high growth in this region can primarily be attributed to the increasing geriatric population, and high disease burden of neurological disorders among senior population
The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 – 28%, Tier 2 – 42%, and Tier 3 – 30%
• By Designation: C-level – 30%, D-level – 34%, and Others – 36%
• By Region: North America – 46%, Europe – 25%, Asia Pacific – 18%, and the Rest of the World – 11%
Lists of Companies Profiled in the Report:

• Medtronic (Ireland)
• Boston Scientific Corporation (US)
• Abbott Laboratories (US)
• LivaNova (UK)
• NeuroPace (US)
• Neuronetics (US)
• Helius Medical Technologies (US)
• Renishaw (UK)
• GTX Medical (Netherlands)
• Bioinduction (UK)
• Bioness (US)
• Nevro Corporation (US)
• BlueWind Medical (Israel)
• Aleva Neurotherapeutics (Switzerland)
• GiMer Medical (Taiwan)
• NeuroSigma (US)
• BioWaveGo USA (US)
• Synapse Biomedical (US)
• Cardionomic (US)
• Theranica Bio-Electronics (Israel)
• MicroTransponder (US)
• Soterix Medical (US)
• Saluda Medical (US)
• Electrocore, Inc. (US)
• tVNS Technologies (Germany).

Neuromodulation Market by Type (Internal (Deep Brain Stimulation, Vagus Nerve Stimulation), External (Transcranial Magnetic Stimulation)), Application (Parkinson's Disease, Depression, Urine incontinence, Epilepsy, Obesity) - Global Forecast to 2027

Research Coverage:
This report provides a detailed picture of the global neuromodulation market. It aims at estimating the size and future growth potential of the market across different segments, such as type, application and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall neuromodulation market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities and challenges.


목차

TABLE OF CONTENTS

1 INTRODUCTION (Page No. – 32)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 NEUROMODULATION MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. – 36)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
TABLE 1 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 4 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS
2.6 RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT: NEUROMODULATION MARKET
2.7 LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY (Page No. – 47)
FIGURE 7 NEUROMODULATION MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 8 INTERNAL NEUROMODULATION MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 9 EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 10 NEUROMODULATION MARKET: GEOGRAPHIC SNAPSHOT

4 PREMIUM INSIGHTS (Page No. – 50)
4.1 NEUROMODULATION MARKET OVERVIEW
FIGURE 11 RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE GROWTH IN NEUROMODULATION MARKET
4.2 NORTH AMERICA: NEUROMODULATION MARKET, BY TYPE & COUNTRY (2021)
FIGURE 12 INTERNAL NEUROMODULATION ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2021
4.3 GEOGRAPHIC GROWTH OPPORTUNITIES IN NEUROMODULATION MARKET
FIGURE 13 COUNTRIES IN ASIA PACIFIC TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. – 52)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 14 NEUROMODULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of neurological disorders and nerve injuries
5.2.1.2 Growing focus on neuromodulation & neurostimulation technologies
5.2.1.3 Expanding applications of neuromodulation
TABLE 3 INDICATIVE LIST OF NEUROMODULATION CLINICAL TRIALS
FIGURE 15 RESEARCH PAPERS PUBLISHED (2011–2021)
5.2.1.4 Growing geriatric population and subsequent increase in prevalence of neurological disorders
5.2.1.5 Government support for research on neurological disorders
FIGURE 16 FUNDING FOR RESEARCH BY NIH (US)
5.2.2 RESTRAINTS
5.2.2.1 High cost of neuromodulation procedures
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging economies
FIGURE 17 GROWTH IN CURRENT PER CAPITA HEALTHCARE EXPENDITURE, 2012–2019
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory frameworks and time-consuming approval processes
5.2.4.2 Preference for drug therapies over neuromodulation products
5.2.4.3 Shortage of trained professionals
5.2.4.4 Product recalls
TABLE 4 MAJOR PRODUCT RECALLS
5.3 SCENARIO-BASED MARKET ASSESSMENT
5.3.1 NEUROMODULATION MARKET
FIGURE 18 PESSIMISTIC SCENARIO
FIGURE 19 OPTIMISTIC SCENARIO
FIGURE 20 REALISTIC SCENARIO
5.4 VALUE CHAIN ANALYSIS
FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE
5.4.1 RESEARCH & DEVELOPMENT
5.4.2 MANUFACTURING & ASSEMBLY
5.4.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
5.5 SUPPLY CHAIN ANALYSIS
FIGURE 22 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.6 TECHNOLOGY ANALYSIS
5.7 PORTER’S FIVE FORCES ANALYSIS
5.7.1 THREAT FROM NEW ENTRANTS
5.7.2 INTENSITY OF COMPETITIVE RIVALRY
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 BARGAINING POWER OF SUPPLIERS
5.7.5 THREAT FROM SUBSTITUTES
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
5.8.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON THE BUYING PROCESS, BY TECHNOLOGY
TABLE 5 INFLUENCE OF STAKEHOLDERS ON THE BUYING PROCESS FOR THE TOP 3 TECHNOLOGIES (%)
5.8.2 BUYING CRITERIA
FIGURE 24 KEY BUYING CRITERIA FOR TOP 2 END USERS
TABLE 6 KEY BUYING CRITERIA, BY END USER
5.9 REGULATORY LANDSCAPE
TABLE 7 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING NEUROMODULATION
5.9.1 BY REGION
5.9.1.1 North America
5.9.1.2 Europe
5.9.1.3 Asia Pacific
5.9.1.3.1 India
5.9.1.3.2 China
5.10 PATENT ANALYSIS
5.11 KEY CONFERENCES AND EVENTS IN 2022
TABLE 8 LIST OF CONFERENCES & EVENTS
5.12 PRICING ANALYSIS
TABLE 9 PRICE RANGE FOR NEUROMODULATION DEVICES AND PROCEDURES
5.13 TRADE ANALYSIS
TABLE 10 IMPORT DATA FOR HS CODE 901890, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 11 EXPORT DATA FOR HS CODE 901890, BY COUNTRY, 2016–2020 (USD MILLION)
5.14 ECOSYSTEM ANALYSIS
5.14.1 ROLE IN ECOSYSTEM
5.14.2 KEY PLAYERS IN THE NEUROMODULATION MARKET
5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES

6 NEUROMODULATION MARKET, BY TYPE (Page No. – 75)
6.1 INTRODUCTION
TABLE 12 NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2 INTERNAL NEUROMODULATION
TABLE 13 INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 14 INTERNAL NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 15 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 16 EUROPE: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 17 ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 18 REST OF THE WORLD: INTERNAL NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.1 SPINAL CORD STIMULATION
6.2.1.1 Growing incidence of spinal cord injuries to support market growth
TABLE 19 SPINAL CORD STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 20 SPINAL CORD STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
TABLE 21 NORTH AMERICA: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 22 EUROPE: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 23 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 24 REST OF THE WORLD: SPINAL CORD STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.2 DEEP BRAIN STIMULATION
6.2.2.1 DBS allows stimulation parameters to be changed to reduce side effects
TABLE 25 DEEP BRAIN STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 26 DEEP BRAIN STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
TABLE 27 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 28 EUROPE: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 29 ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 30 REST OF THE WORLD: DEEP BRAIN STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.3 VAGUS NERVE STIMULATION
6.2.3.1 Non-invasive vagus nerve stimulation does not require surgical implantation—a key benefit
TABLE 31 VAGUS NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 32 VAGUS NERVE STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
TABLE 33 NORTH AMERICA: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 34 EUROPE: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 35 ASIA PACIFIC: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 36 REST OF THE WORLD: VAGUS NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.4 SACRAL NERVE STIMULATION
6.2.4.1 Widening scope of sacral nerve stimulation to drive growth
TABLE 37 SACRAL NERVE STIMULATION DEVICES OFFERED
TABLE 38 SACRAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 39 SACRAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
TABLE 40 NORTH AMERICA: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 41 EUROPE: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 42 ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 43 REST OF THE WORLD: SACRAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.5 GASTRIC ELECTRICAL STIMULATION
6.2.5.1 Growing number of people suffering from severe GERD and gastroparesis to fuel market growth
TABLE 44 GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 45 GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
TABLE 46 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 47 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 48 ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 49 REST OF THE WORLD: GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3 EXTERNAL NEUROMODULATION
TABLE 50 EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 51 EXTERNAL NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 52 NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 53 EUROPE: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 54 ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 55 REST OF THE WORLD: EXTERNAL NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION
6.3.1.1 Extensive use in healthcare, low cost, and ease of use to favor market growth
TABLE 56 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 57 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
TABLE 58 NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 59 EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 60 ASIA PACIFIC: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 61 REST OF THE WORLD: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.2 TRANSCRANIAL MAGNETIC STIMULATION
6.3.2.1 Minimal patient discomfort associated with TMS supports demand
TABLE 62 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 63 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
TABLE 64 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 65 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 66 ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 67 REST OF THE WORLD: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.3 RESPIRATORY ELECTRICAL STIMULATION
6.3.3.1 High treatment efficacy to fuel market growth
TABLE 68 RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 69 RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
TABLE 70 NORTH AMERICA: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 71 EUROPE: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 72 ASIA PACIFIC: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 73 REST OF THE WORLD: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)

7 NEUROMODULATION MARKET, BY APPLICATION (Page No. – 102)
7.1 INTRODUCTION
7.2 SPINAL CORD STIMULATION MARKET, BY APPLICATION
TABLE 74 SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.2.1 CHRONIC PAIN
7.2.1.1 High incidence of chronic pain supports market growth
TABLE 75 SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY REGION, 2020–2027 (USD MILLION)
7.2.2 FAILED BACK SURGERY SYNDROME
7.2.2.1 Growing incidence of FBSS due to rising number of surgeries each year to drive demand for stimulation technologies
TABLE 76 SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY REGION, 2020–2027 (USD MILLION)
7.2.3 ISCHEMIA
7.2.3.1 High effectiveness of neuromodulation for ischemia treatment to support market growth
TABLE 77 SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY REGION, 2020–2027 (USD MILLION)
7.3 DEEP BRAIN STIMULATION MARKET, BY APPLICATION
TABLE 78 DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.3.1 PARKINSON’S DISEASE
7.3.1.1 Rising incidence of Parkinson’s disease and growing R&D activity in this area to drive growth
TABLE 79 DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY REGION, 2020–2027 (USD MILLION)
7.3.2 TREMORS
7.3.2.1 High efficacy of DBS in treating tremors boosts demand
TABLE 80 DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY REGION, 2020–2027 (USD MILLION)
7.3.3 DEPRESSION
7.3.3.1 Lack of evidence of efficacy of DBS for depression treatment to limit market growth
TABLE 81 DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY REGION, 2020–2027 (USD MILLION)
7.3.4 OTHER DBS APPLICATIONS
TABLE 82 DEEP BRAIN STIMULATION MARKET FOR OTHER DBS APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
7.4 SACRAL NERVE STIMULATION MARKET, BY APPLICATION
TABLE 83 SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.4.1 URINE INCONTINENCE
7.4.1.1 High incidence of urine incontinence offers growth opportunities
TABLE 84 SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY REGION, 2020–2027 (USD MILLION)
7.4.2 FECAL INCONTINENCE
7.4.2.1 Reduced symptom recurrence supports use of SNS in fecal incontinence treatment
TABLE 85 SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY REGION, 2020–2027 (USD MILLION)
7.5 VAGUS NERVE STIMULATION MARKET, BY APPLICATION
TABLE 86 VAGUS NERVE MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.5.1 EPILEPSY
7.5.1.1 Advantages associated with VNS in epilepsy treatment to propel market
TABLE 87 VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY REGION, 2020–2027 (USD MILLION)
7.5.2 OTHER VNS APPLICATIONS
TABLE 88 VAGUS NERVE STIMULATION MARKET FOR OTHER VNS APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
7.6 GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION
TABLE 89 GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.6.1 GASTROPARESIS
7.6.1.1 GES treatment reduces hospitalizations for patients affected by gastroparesis
TABLE 90 GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY REGION, 2020–2027 (USD MILLION)
7.6.2 OBESITY
7.6.2.1 Risks associated with gastric bypass to increase preference for GES
TABLE 91 GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY REGION, 2020–2027 (USD MILLION)
7.7 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION
TABLE 92 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.7.1 TREATMENT-RESISTANT DEPRESSION
7.7.1.1 TENS induces relaxed state in patients suffering from treatment-resistant depression
TABLE 93 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY REGION, 2020–2027 (USD MILLION)
7.7.2 OTHER TENS APPLICATIONS
TABLE 94 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR OTHER TENS APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
7.8 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION
TABLE 95 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.8.1 DEPRESSION
7.8.1.1 Increased acceptance among patients to drive demand for TMS
TABLE 96 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY REGION, 2020–2027 (USD MILLION)
7.8.2 MIGRAINE
7.8.2.1 High prevalence of migraine to support market growth
TABLE 97 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY REGION, 2020–2027 (USD MILLION)
7.9 RESPIRATORY ELECTRICAL STIMULATION MARKET, BY APPLICATION
7.9.1 SPINAL CORD INJURY
7.9.1.1 Rising incidence of spinal cord injuries ensures sustained demand for RES
TABLE 98 RESPIRATORY ELECTRICAL STIMULATION MARKET FOR SPINAL CORD INJURY, BY REGION, 2020–2027 (USD MILLION)

8 NEUROMODULATION MARKET, BY REGION (Page No. – 117)
8.1 INTRODUCTION
TABLE 99 NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
8.2 NORTH AMERICA
FIGURE 25 NORTH AMERICA: NEUROMODULATION MARKET SNAPSHOT
TABLE 100 NORTH AMERICA: NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 101 NORTH AMERICA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 102 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 103 NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 104 NORTH AMERICA: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 105 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 106 NORTH AMERICA: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 107 NORTH AMERICA: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 108 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 109 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 110 NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.2.1 US
8.2.1.1 Large number of prominent players makes US the largest market
TABLE 111 US: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 112 US: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 113 US: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.2.2 CANADA
8.2.2.1 Rising healthcare expenditure and increasing disease prevalence will drive demand for neurostimulation
TABLE 114 NEUROLOGICAL CONDITIONS PREVALENT IN CANADA
TABLE 115 CANADA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 116 CANADA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 117 CANADA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3 EUROPE
TABLE 118 EUROPE: NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 119 EUROPE: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 120 EUROPE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 121 EUROPE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 122 EUROPE: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 123 EUROPE: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 124 EUROPE: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 125 EUROPE: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)           TABLE 126 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 127 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 128 EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.3.1 GERMANY
8.3.1.1 Favorable government initiatives ensure strong market growth in Germany
TABLE 129 GERMANY: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 130 GERMANY: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 131 GERMANY: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.2 UK
8.3.2.1 High public- and private-sector investments fuel market growth
TABLE 132 UK: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 133 UK: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 134 UK: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.3 FRANCE
8.3.3.1 Availability of insurance and favorable healthcare reforms contribute to growth
TABLE 135 FRANCE: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 136 FRANCE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 137 FRANCE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.4 ITALY
8.3.4.1 Easy access to healthcare services makes Italy a lucrative market
TABLE 138 ITALY: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 139 ITALY: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 140 ITALY: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.5 SPAIN
8.3.5.1 Growing government initiatives may support market growth in Spain
TABLE 141 SPAIN: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 142 SPAIN: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 143 SPAIN: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.6 REST OF EUROPE
TABLE 144 PERCENTAGE OF POPULATION AGED 65 YEARS OR OVER, 2019 VS. 2050
TABLE 145 REST OF EUROPE: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 146 REST OF EUROPE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 147 REST OF EUROPE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4 ASIA PACIFIC
FIGURE 26 ASIA PACIFIC: NEUROMODULATION MARKET SNAPSHOT
TABLE 148 ASIA PACIFIC: NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 149 ASIA PACIFIC: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 150 ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 151 ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 152 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 153 ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 154 ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 155 ASIA PACIFIC: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 156 ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 157 ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 158 ASIA PACIFIC: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.4.1 JAPAN
8.4.1.1 Japan dominates the APAC market for neuromodulation
TABLE 159 JAPAN: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 160 JAPAN: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 161 JAPAN: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.2 CHINA
8.4.2.1 Growing geriatric population will favor market growth in China
TABLE 162 CHINA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 163 CHINA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 164 CHINA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.3 INDIA
8.4.3.1 Improvements in healthcare infrastructure in the country will support market
TABLE 165 INDIA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 166 INDIA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 167 INDIA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.4 REST OF ASIA PACIFIC
TABLE 168 REST OF ASIA PACIFIC: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 169 REST OF ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 170 REST OF ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.5 REST OF THE WORLD
TABLE 171 REST OF THE WORLD: NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 172 REST OF THE WORLD: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 173 REST OF THE WORLD: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 174 REST OF THE WORLD: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 175 REST OF THE WORLD: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 176 REST OF THE WORLD: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 177 REST OF THE WORLD: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 178 REST OF THE WORLD: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 179 REST OF THE WORLD: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 180 REST OF THE WORLD: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 181 REST OF THE WORLD: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.5.1 LATIN AMERICA
8.5.1.1 Latin America holds largest share of neuromodulation market in RoW
TABLE 182 LATIN AMERICA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 183 LATIN AMERICA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 184 LATIN AMERICA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.5.2 MIDDLE EAST & AFRICA
8.5.2.1 High cost of neuromodulation to hamper market growth
TABLE 185 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 186 MIDDLE EAST & AFRICA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 187 MIDDLE EAST & AFRICA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)

9 COMPETITIVE LANDSCAPE (Page No. – 158)
9.1 OVERVIEW
9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
TABLE 188 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
9.3 REVENUE SHARE ANALYSIS
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN NEUROMODULATION MARKET
9.4 MARKET SHARE ANALYSIS
TABLE 189 NEUROMODULATION MARKET: DEGREE OF COMPETITION
9.5 COMPANY EVALUATION MATRIX
9.5.1 STARS
9.5.2 EMERGING LEADERS
9.5.3 PERVASIVE PLAYERS
9.5.4 PARTICIPANTS
FIGURE 28 COMPANY EVALUATION MATRIX: NEUROMODULATION MARKET
9.6 COMPANY EVALUATION MATRIX FOR SMES/START-UPS
9.6.1 PROGRESSIVE COMPANIES
9.6.2 STARTING BLOCKS
9.6.3 RESPONSIVE COMPANIES
9.6.4 DYNAMIC COMPANIES
FIGURE 29 COMPANY EVALUATION MATRIX FOR SMES/START-UPS: NEUROMODULATION MARKET
9.7 COMPANY FOOTPRINT ANALYSIS
TABLE 190 OVERALL FOOTPRINT OF COMPANIES
TABLE 191 REGIONAL FOOTPRINT OF COMPANIES
TABLE 192 TYPE FOOTPRINT OF COMPANIES
9.8 COMPETITIVE BENCHMARKING
TABLE 193 NEUROMODULATION MARKET: DETAILED LIST OF KEY START-UPS/SMES
9.9 COMPETITIVE SCENARIO
9.9.1 PRODUCT LAUNCHES & APPROVALS
TABLE 194 KEY PRODUCT LAUNCHES & APPROVALS
9.9.2 DEALS
TABLE 195 KEY DEALS
9.9.3 OTHER DEVELOPMENTS
TABLE 196 OTHER KEY DEVELOPMENTS

10 COMPANY PROFILES (Page No. – 170)
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1 KEY PLAYERS
10.1.1 MEDTRONIC PLC
TABLE 197 MEDTRONIC PLC: BUSINESS OVERVIEW
FIGURE 30 MEDTRONIC PLC: COMPANY SNAPSHOT (2021)
10.1.2 BOSTON SCIENTIFIC CORPORATION
TABLE 198 BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW
FIGURE 31 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2021)
10.1.3 ABBOTT LABORATORIES
TABLE 199 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 32 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
10.1.4 LIVANOVA PLC
TABLE 200 LIVANOVA PLC: BUSINESS OVERVIEW
FIGURE 33 LIVANOVA PLC: COMPANY SNAPSHOT (2021)
10.1.5 NEVRO CORPORATION
TABLE 201 NEVRO CORPORATION: BUSINESS OVERVIEW
FIGURE 34 NEVRO CORPORATION: COMPANY SNAPSHOT (2021)
10.1.6 NEUROSIGMA, INC.
TABLE 202 NEUROSIGMA, INC.: BUSINESS OVERVIEW
10.1.7 NEUROPACE, INC.
TABLE 203 NEUROPACE, INC.: BUSINESS OVERVIEW
FIGURE 35 NEUROPACE, INC.: COMPANY SNAPSHOT (2021)
10.1.8 SOTERIX MEDICAL INC.
TABLE 204 SOTERIX MEDICAL INC.: BUSINESS OVERVIEW
10.1.9 SYNAPSE BIOMEDICAL INC.
TABLE 205 SYNAPSE BIOMEDICAL INC.: BUSINESS OVERVIEW
10.1.10 ALEVA NEUROTHERAPEUTICS SA
TABLE 206 ALEVA NEUROTHERAPEUTICS SA: BUSINESS OVERVIEW
10.1.11 THERANICA BIO-ELECTRONICS LTD.
TABLE 207 THERANICA BIO-ELECTRONICS LTD.: BUSINESS OVERVIEW
10.1.12 NEURONETICS
TABLE 208 NEURONETICS: BUSINESS OVERVIEW
FIGURE 36 NEURONETICS: COMPANY SNAPSHOT (2021)
10.1.13 BIONESS
TABLE 209 BIONESS: BUSINESS OVERVIEW
10.1.14 BIOINDUCTION
TABLE 210 BIOINDUCTION: BUSINESS OVERVIEW
10.2 OTHER PLAYERS
10.2.1 GIMER MEDICAL
10.2.2 GTX MEDICAL
10.2.3 HELIUS MEDICAL TECHNOLOGIES
10.2.4 MICROTRANSPONDER
10.2.5 BLUEWIND MEDICAL
10.2.6 ELECTROCORE, INC.
10.2.7 RENISHAW PLC
10.2.8 TVNS TECHNOLOGIES GMBH
10.2.9 BIOWAVEGO USA
10.2.10 CARDIONOMIC, INC.
10.2.11 SALUDA MEDICAL PTY LTD.

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

11 APPENDIX (Page No. – 207)
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 AVAILABLE CUSTOMIZATIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS


    • 리포트 제목은 자동으로 입력됩니다.
    • *항목은 필수항목입니다.

    의뢰분류*

    성함*

    회사명*

    부서명

    이메일*

    전화번호

    저희 사이트를 알게 된 경로를 가르쳐 주세요.

    문의 내용*

     

    ※개인정보보호정책은여기에서 확인 가능합니다。

    Email 문의도 받고 있습니다.
    아래 주소이며 죄송하지만 "(at)"을 "@"로 바꾸어 보내주시길 부탁드립니다.
    mooneui(at)chosareport-korea.com